Pharsight

CELGENE PATENTS FACING OPPOSITIONS

Top patents of CELGENE facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP3692983B1 11 Aug, 2021 Oral formulations of cytidine analogs and methods of use thereof May, 2029 6
EP3782611B1 06 Jul, 2022 Oral formulations of cytidine analogs and methods of use thereof May, 2029 5
EP2223688B1 29 May, 2019 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof Mar, 2023 5
EP3042659B8 19 Dec, 2018 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione Sep, 2024 5
EP2695609B1 11 Dec, 2019 Oral formulations of cytidine analogs and methods of use thereof NA 4
EP3351240B1 10 Apr, 2019 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione NA 4
EP2299984B1 28 Nov, 2018 Oral formulations of cytidine analogs and methods of use thereof NA 2
EP3880802B1 07 Sep, 2022 Improved t cell manufacturing process Nov, 2039 1
EP2687213B1 23 Jan, 2019 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof Mar, 2028 1
EP3045175B8 19 Dec, 2018 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione Sep, 2024 1
EP3045176B8 12 Dec, 2018 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione Sep, 2024 1
EP2223687B1 17 May, 2017 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof Mar, 2023 1